Schering gets EU nod for PET (positron emission tomography) cancer agent:
This article was originally published in Clinica
Executive Summary
Schering has gained the go-ahead in Europe to market its positron emission tomography (PET) imaging agent, Flucis, for diagnosing cancer. The agent, which can also help doctors monitor, stage and detect disease recurrence, has several indications, including head and neck cancer, lung cancer and malignant lymphomas. Other indications include the staging and detection of recurrences from colorectal cancer and melanoma.